Multiple Sclerosis World Market Outlook to 2011

Multiple Sclerosis World Market Outlook to 2011

Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS that causes significant disability in young adults. Worldwide, millions of people are affected by multiple sclerosis. Although there is no cure, approved treatments are available to slow the progression of MS and offer improved quality of life.
The market for these treatments has grown 15% since 2004 and continued double-digit growth is expected in the near term. Kalorama Information's: Multiple Sclerosis: A Market Briefing takes a detailed look at multiple sclerois worldwide and the market for MS treatments, as well as treatments that will be available in the future. Kalorama's study focusing on the following four treatments:

Copaxone
Avonex
Rebif
Betaseron/Betaferon
As part of its continuing coverage, this report provides:

Overview of Multiple Sclerosis and its Progression.
Complete Incidence and Prevalence Statistics For U.S. and Worldwide.
Triggers and Risk Factors of MS.
Review of Multiple Sclerosis Treatments on the Market
Market Size and Forecasts For Treatements to 2011.
Issues and Trendsfacing MS treatment
New Multiple Sclerosis Treatments in the pipleline.
As part of Kalorama's trusted information -gathering process, intensive research into company, trade and medical literature was supplemented by interviews with experts in the multiple sclerosis treatment industry. Interviews make up the source of forecast and market size figures.
The Multiple Sclerosis market is examined for the U.S., European and Japanese markets.

CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Size and Growth of the Market
Issues an Trends Affecting Market
Leading Competitors

CHAPTER TWO: INTRODUCTION
Introduction to Multiple Sclerosis
Progression of Multiple Sclerosis
Relapsing-remitting MS
Primary-progressive MS
Secondary-progressive MS
Progressive-relapsing MS
Benign MS
Pathogenesis of MS
Inflammatory Response and MS
Triggers
Risk Factors
Physical Complications of MS
Diagnosing MS
Demographics and Statistics

CHAPTER THREE: TREATMENTS FOR MULTIPLE SCLEROSIS
Description of Products
Copaxone
Avonex
Rebif
Betaferon/Betaseron
Tysabri
Novantrone
Research and Development
Late Stage Development
Early to Mid Stage Development
Phase II Development
Phase I Development
Preclinical Development and Research
Experimental Drugs and Treatments
Discontinued Development
Market and Competitive Analysis
World Market Analysis
World Competitive Analysis
Markets by World Region
U.S. Market
Europe Market
Japan Market

CHAPTER FOUR: ISSUES AND TRENDS AFFECTING THE MS MARKET
Introduction
Medicare and Health Insurance Issues
NIH MS Funding Reduction
Stem Cell Controversy and MS
Access to Life-Saving Medicine Act and MS
Par-3 Discovery
Cyclophilin D Regulation
Women and MS
Pregnancy and MS
Alternative Therapies in MS Treatment
MS and Diabetes

CHAPTER FIVE: COMPANY PROFILES
Bayer Schering Pharma AG
Biogen IDEC
Novartis AG
Sanofi-Aventis
Merck Serono S.A.
Teva Pharmaceutical Industries Ltd
APPENDIX: COMPANY NAMES AND ADDRESSES

TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: Multiple Sclerosis Cases in Selected Countries.
Table 1-2: The Worldwide Multiple Sclerosis Market 2004-2011
Figure 1-1: The Worldwide Multiple Sclerosis Market 2004-2011
CHAPTER TWO: INTRODUCTION
Table 2-1: Estimated World Prevalence of Multiple Sclerosis by Selected Countries
Figure 2-1: Estimated World Prevalence of Multiple Sclerosis by Selected Countries
Table 2-2: World Population by Selected Geographical Region, 2006-2050
Figure 2-2: World Population by Selected Geographical Region, 2006-2050
Table 2-2: World Population by Selected Countries, 2006
Figure 2-3: World Population by Selected Countries, 2006
Table 2-3: Estimated World Population by Age, sex and Geographical Region, 2006
Figure 2-4: Estimated World Population by Age and Geographical Region, 2006
Figure 2-5: Estimated World Population by Sex and Geographical Region, 2006
CHAPTER THREE: TREATMENTS FOR MULTIPLE SCLEROSIS
Table 3-1: Currently Available Multiple Sclerosis
Treatments (Brand Name, Generic Name, Marketer and Approval Dates)
Table 3-2: Estimated World Sales for Leading Products, 2004-2006
Figure 3-1: Estimated World Sales for Leading Products, 2006
Figure 3-2: Estimated World Sales for Leading Products 2004-2006
Figure 3-3: Estimated World Sales for Leading Products, 2006
Table 3-3: Multiple Sclerosis Products in Late Stage Development
Table 3-4: Multiple Sclerosis Products in Early to Mid-Stage Development
Table 3-5: The Worldwide Multiple Sclerosis Market 2004-2011
Figure 3-4: The Worldwide Multiple Sclerosis Market 2004-2011
Table 3-6: The Worldwide Multiple Sclerosis Market Estimated Revenues and Market Share of Leading Suppliers 2006
Figure 3-5: The Worldwide Multiple Sclerosis Market Estimated Market Share by Leading Suppliers 2001
Table 3-7: The Worldwide Multiple Sclerosis Market Projected Revenues and Market Share of Leading Suppliers 2011
Figure 3-6: The Worldwide Multiple Sclerosis Market Projected Market Share by Leading Suppliers 2011
Table 3-8: The Worldwide Multiple Sclerosis Market Estimated Products Sales by Geographic Region, 2004-2006
Figure 3-7: The Worldwide Multiple Sclerosis Market Estimated Products Sales by Geographic Region, 2004-2006
Figure 3-8: The Worldwide Multiple Sclerosis Market Estimated Products Sales by Geographic Region, 2004
Figure 3-9: The Worldwide Multiple Sclerosis Market Estimated Products Sales by Geographic Region, 2005
Figure 3-10: The Worldwide Multiple Sclerosis Market Estimated Products Sales by Geographic Region, 2006
Table 3-9: The U.S. Multiple Sclerosis Market Estimated Revenues and Market Share of Leading Suppliers 2006
Figure 3-13: The U.S. Multiple Sclerosis Market Projected Market Share by Leading Suppliers 2006
Table 3-10: The European Multiple Sclerosis Market Estimated Revenues and Market Share of Leading Suppliers 2006
Figure 3-14: The European Multiple Sclerosis Market Projected Market Share by Leading Suppliers 2006
Table 3-11: The Japanese Multiple Sclerosis Market Estimated Revenues and Market Share of Leading Suppliers 2006
Figure 3-15: The Japanese Multiple Sclerosis Market Projected Market Share by Leading Suppliers 2006
CHAPTER FOUR: ISSUES AND TRENDS AFFECTING THE MS MARKET
Table 4-1: NIH Funding By Year